Jiangxi Biopharmaceuticals (06915.HK) wholly-owned subsidiary receives approval document for animal tetanus antitoxin batch number.

date
03/07/2026
The Zhixin Finance APP News reported that Jiangxi Bio (06915.HK) announced that its wholly-owned subsidiary, Chifeng Bon Medicine Co., Ltd., has recently obtained the Approval Number for its tetanus antitoxin for veterinary use.